Gene silencing technologies have suggested a few testable combinations of targeted therapy in NSCLC, for example, SHP2 and ALK inhibitors (21), FGFR and m-TOR inhibitors (22), or FGFR and EGFR inhibitors (23). Here, ALK is linked to non-small cell lung carcinoma.